Navigation Links
Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection

SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. , a biopharmaceutical company committed to the discovery, development and commercialization of novel medicines for the treatment of hepatitis and cancer, announced today that it has nominated ANA598 as a candidate for clinical development as an orally-administered direct antiviral for the treatment of chronic hepatitis C virus (HCV) infection.

"We have identified a small-molecule, non-nucleoside inhibitor of the NS5b polymerase that, based on pre-clinical studies conducted to date, has shown favorable antiviral, metabolic, pharmacokinetic, and preliminary toxicologic properties, and is the culmination of several years of work in our HCV direct antiviral discovery program," said Lawrence C. Fritz, Ph.D., president and chief executive officer of Anadys. "We are now conducting additional pre-clinical studies in anticipation of submitting an Investigational New Drug application (IND) in the second quarter of 2008."

Preclinical Study Results

In a series of in vitro pre-clinical studies ANA598 demonstrated excellent potency against HCV genotype 1 NS5b polymerase and potent activity in HCV replicon assays. The compound also displayed very good in vitro metabolic stability and did not significantly inhibit human CYP enzymes, suggesting a low potential for drug-drug interactions. Extending these in vitro findings, in vivo preclinical studies of ANA598 demonstrated high oral bioavailability and good tolerability. Also, drug levels were sustained in the plasma and in the liver, the principal site of HCV replication.

"The current standard of care is inadequate for many chronic HCV patients, including about half of those with genotype 1 disease," said Steve Worland, Ph.D., president, Pharmaceuticals. "We believe ANA598 possesses favorable characteristics that may enable it to play an important role in future HCV thera
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/23/2014)... YORK , July 23, 2014  When it comes ... Wagner is ready to roll out the red carpet. ... welcome an influx of HAL 9000-like robots into our human ... right now, there,s a pressing need to apply new technologies ... The worldwide market for medical robotics is expected to increase ...
(Date:7/23/2014)... July 23, 2014 Research and Markets ... Medical Gloves (Exam and Surgical) Markets Worldwide 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 The purpose of this report ... Disposable Medical (Exam and Surgical) Gloves. The report discusses ... these products. Topics covered include product definitions, ...
(Date:7/23/2014)... July 23, 2014  Lightlake Therapeutics Inc. ("Lightlake") ... based on its expertise in opioid antagonists, announced ... drug application ("IND") with respect to its naloxone-based ... today that it has received an additional commitment ... part of the National Institutes of Health ("NIH"), ...
Breaking Medicine Technology:Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 3Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 4Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
... Pharmaceuticals, Inc. (NASDAQ: IDIX ), a biopharmaceutical company ... treatment of human viral diseases, today announced that it has ... common stock. All of these shares are being sold by ... sole book-running manager and underwriter for the offering.  Idenix intends ...
... RSB Spine, LLC, today announced allowance of ... its line of InterPlate® cervical and lumbar intervertebral ... of the most common spinal procedures performed by ... numerous disc replacement implants," commented James M. Moran, ...
Cached Medicine Technology:Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock 2
(Date:7/23/2014)... Karen Pallarito HealthDay Reporter ... wild day for Obamacare, two federal appeals courts arrived at ... provided to millions of Americans who bought health insurance through ... the matter is headed for a showdown before the U.S. ... U.S. Appeals Court for the District of Columbia Circuit said ...
(Date:7/23/2014)... The European Vitamins Market report explains ... and projection of revenue. The market in Europe is ... to $1,202.08 million by 2018, at a CAGR of ... TOC of the European Vitamins Market report, to get ... provides a glimpse of the segmentation in the European ...
(Date:7/23/2014)... The European Bio fertilizers Market Report defines ... analysis and forecast of revenue. The bio fertilizers market ... 2,566.4 million in 2012 to $4,582.2 million by 2017, ... , Browse through the TOC of the European Bio ... in-depth analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-fertilizer-4637178345.html , ...
(Date:7/23/2014)... Bethesda, MD (July 23, 2014) Statins, a class ... reduce a patient,s risk of developing Barrett,s esophagus, according ... , the official journal of the American ... risk reduction with statin use. , "Patients who received ... of having Barrett,s esophagus compared to non-users," said study ...
(Date:7/23/2014)... July 23, 2014 According to a ... by Form Factor (Integrated Circuit IP, SOC IP), Design ... Application, Geography and Verification IP - Forecast & Analysis ... is expected to grow at a CAGR of 12.6% ... 2020. , Browse more than 76 market data tables ...
Breaking Medicine News(10 mins):Health News:2 Courts, 2 Different Decisions on Key Obamacare Provision 2Health News:2 Courts, 2 Different Decisions on Key Obamacare Provision 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 2Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 3Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 4Health News:Statin use decreases the risk of Barrett's esophagus 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 6
... a leading provider of laser vision correction services under ... center in Des,Moines, Iowa. This marks the 74th LasikPlus ... vision center in the state of Iowa.,LasikPlus vision centers ... Similar to other LasikPlus vision centers throughout the ...
... Highlights Myriad Opportunities for Using Wireless ... Efficiency and Accuracy of Patient Care, WALTHAM, Mass., ... intelligent wireless LANs (WLANs) for enterprises and,service providers, will ... Exhibition, taking place February 24-28 in Orlando, FL, to,showcase ...
... ECG Devices Help Healthcare Organizations Deliver Clinical ... Data Faster and ... Networks, the leading,global provider of intelligent wireless LANs (WLANs) ... Corporation,(Nasdaq: CSCX ) ( http://www.cardiacscience.com ), the leading ...
... of, CellCept Will Provide Effective Treatment Options, According ... ... Feb. 25 Decision Resources, one of the,world,s leading research ... entry and uptake of high-priced branded,agents will drive the systemic ...
... HealthVault Empowers Patients to Orchestrate Health ... ... the leading provider,of next generation healthcare connectivity solutions, today announced ... using Microsoft(R) HealthVault(TM), at the 2008 HIMSS,(Healthcare Information and Management ...
... Hyperion,Therapeutics, Inc. today announced that the first ... trial of AMMONUL(R) (sodium phenylacetate and sodium,benzoate) Injection ... hepatic,encephalopathy (HE). The randomized, double-blind study is designed ... standard of care in,hospitalized adults. The FDA has ...
Cached Medicine News:Health News:LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa 2Health News:Colubris Demonstrates Wide-Ranging Mobility Solutions for Healthcare 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 3Health News:Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 3Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 2Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 3
Scorpio CR Knee is designed to address normal knee kinematics, range of motion (ROM) and polyethylene wear....
... TC-PLUS Solution tricompartmental total knee prosthesis stems ... arthroplasty. State-of-the-art design and manufacturing technologies have ... biomechanical function as well as a favorable ... insert to keep wear to a minimum. ...
... Knee System has been ... refined with the aid ... and manufacturing technology. Its ... stability, function, performance and ...
... image guided surgery system offers full-featured ... design and use. It provides unparalleled ... localize critical anatomy and plan optimal ... surgeons an easy-to-use, technologically advanced approach ...
Medicine Products: